For Healthcare Professionals: Lymphomas

Our specialists care for more than 1,200 individuals newly diagnosed with lymphoma each year, as well as many others receiving ongoing and follow-up care. A multidisciplinary team of physicians that includes medical and radiation oncologists and surgeons focuses its expertise on each case, personalizing care.

Most patients with Hodgkin lymphoma have very good outcomes at our institution, and recent second-line treatment strategies have improved prospects for positive tumor response, reduced toxicity, and increased stem cell harvest for transplantation in patients with relapse. Recent data (2010) indicate a five-year cure rate of nearly 70 percent for patients following autologous transplant for relapsed Hodgkin lymphoma, compared to national averages of 45 to 50 percent as reported by the Bone Marrow Transplant Registry.

Refering a Patient

Call 866-218-8132
Mon–Fri, 8:30 AM–5:30 PM, ET

Find an Expert | See Clinical Trials | Request a Pathology Consult

Pictured: Steven Horwitz
Lymphoma Information for Your Patients

The Memorial Sloan Kettering approach to diagnosis and treatment of lymphomas in patient-friendly language.

Pictured: Steven Horwitz
Pictured: Peter Steinherz
Pediatric Lymphoma Information for Your Patients

The Memorial Sloan Kettering approach to diagnosis and treatment of pediatric lymphoma in patient-friendly language.

Pictured: Peter Steinherz

E-Publications for Medical Professionals

Stay up-to-date on Memorial Sloan Kettering advances in your areas of interest.

Subscribe to OncoNotes »

Pictured: Matthew Lunning
Predictor of Transplantation Failure in Relapsed and Refractory Follicular Lymphoma (2012 ASH Conference)

Fellow Matthew Lunning describes a retrospective study that examined event-free and overall survival among patients with relapsed/refractory follicular lymphoma.

Pictured: Alexander Lesokhin
Phase I Clinical Trial of Anti-PD-1 in Hematologic Malignancy

Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.

Pictured: Dan Douer
Clinical Trial: BMS-906024 for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Hematologist-oncologist Don Douer discusses a Phase I clinical trial of intravenous BMS-906024.

Pictured: Matthew Lunning
Predictors of Failure
Pictured: Alexander Lesokhin
Trial of Anti-PD-1
Pictured: Dan Douer
Trial of BMS-906024